Meeting
2023 ASCO Annual Meeting
Overall and non-lung cancer incidence in the National Lung Screening Trial (NLST) as indicators of potential for multi-cancer screening.
Authors
Ellen T. Chang
GRAIL, LLC, a subsidiary of Illumina, Inc., currently held separate from Illumina, Inc., under the terms of the Interim Measures Order of the European Commission dated 29 October 2021, Menlo Park, CA
Ellen T. Chang , Sam M. Janes , Allan Hackshaw , Christina A. Clarke Dur , Diana SM Buist , Earl A. Hubbell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Etiology/Epidemiology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10633)
DOI
10.1200/JCO.2023.41.16_suppl.10633
Abstract #
10633
Poster Bd #
266
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
High incidence of concurrent disease states detected during mobile lung cancer screening in an underserved population.
First Author: Daniel R. Carrizosa
Poster
2017 Genitourinary Cancers Symposium
Second primary lung cancer in the United States: 1992–2008.
First Author: Nicholas Donin
First Author: Lakshmi Kolandra
Poster
2023 ASCO Annual Meeting
A multivariate analysis of low-dose CT lung cancer screening in a Michigan community hospital network.
First Author: Jason Law